Terminated PHASE4 INTERVENTIONAL 2-arm NCT05201703

Fycompa in Catamenial Epilepsy

Pilot Study of Add-On Fycompa (Perampanel)Treatment for Catamenial Epilepsy

Sponsor: Eisai Inc.

Interventions Fycompa Fycompa with a boost

Updated 8 times since 2022 Last updated: Jul 30, 2024 Started: Mar 9, 2022 Primary completion: Dec 15, 2023 Completion: Dec 15, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor enrollment

Other terminated trials from Eisai Inc.

More terminations from Eisai Inc.

This PHASE4 trial investigates Catamenial Epilepsy and is currently terminated or withdrawn. Eisai Inc. leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Aug 2024 — Sep 2024 [monthly]

Terminated PHASE4

Status: Recruiting → Terminated
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE4
Jul 2023 — Jul 2024 [monthly]

Recruiting PHASE4
Nov 2022 — Jul 2023 [monthly]

Recruiting PHASE4

▶ Show 3 earlier versions

Jul 2022 — Nov 2022 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Mar 2022 — Jul 2022 [monthly]

Not Yet Recruiting PHASE4
Feb 2022 — Mar 2022 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Inc.
University of Florida

Data source: University of Florida

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jacksonville, United States